{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:00:52Z","timestamp":1785279652049,"version":"3.55.0"},"reference-count":48,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Klin Monbl Augenheilkd"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1055\/a-2255-5937","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T19:42:26Z","timestamp":1709062946000},"page":"e7-e22","source":"Crossref","is-referenced-by-count":0,"title":["Medikament\u00f6se Therapie von malignen Lidtumoren"],"prefix":"10.1055","volume":"241","author":[{"given":"Daniel","family":"Walsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Furashova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Emmert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinodh","family":"Kakkassery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,2,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"804","DOI":"10.5114\/ada.2020.95652","article-title":"The prevalence of various eyelid skin lesions in a single-centre observation study","volume":"38","author":"W Z Adamski","year":"2021","journal-title":"Adv Dermatol Alergol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/DAD.0b013e3181961861","article-title":"Clinicopathological features of eyelid skin tumors. a retrospective study of 5504 cases\n          and review of literature","volume":"31","author":"M Deprez","year":"2009","journal-title":"Am J Dermatopathology"},{"key":"ref3","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-36606-3","volume-title":"Eyelid and Conjunctival Tumors","author":"M Kaspi","year":"2020"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"100227","DOI":"10.1016\/j.xops.2022.100227","article-title":"Prevalence of and associated factors for eyelid cancer in the American Academy of\n          Ophthalmology Intelligent Research in Sight Registry","volume":"3","author":"Z Ba\u015f","year":"2023","journal-title":"Ophthalmology Science"},{"key":"ref5","first-page":"e43","article-title":"Identifying predictive morphologic features of malignancy in eyelid lesions: The LUI\n          triage key","volume":"61","author":"C Leung","year":"2015","journal-title":"Canadian Family Physician"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s12312-020-00746-7","article-title":"S3-Leitlinie \u201eAktinische Keratose und Plattenepithelkarzinom der Haut\u201c","volume":"35","author":"C Berking","year":"2020","journal-title":"Forum Fam Plan West Hemisph"},{"issue":"10","key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14307_g","article-title":"S3-Leitlinie zur Diagnostik, Therapie und Nachsorge des Melanoms","volume":"18","author":"T K Eigentler","year":"2020","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e699","DOI":"10.1016\/S1470-2045(19)30673-4","article-title":"Sebaceous carcinoma: evidence-based clinical practice guidelines","volume":"20","author":"J L Owen","year":"2019","journal-title":"Lancet Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ajo.2017.02.004","article-title":"Lymphoma of the eyelid \u2013 an international multicenter retrospective study","volume":"177","author":"F H Svendsen","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1093\/jrr\/rrz046","article-title":"Radiotherapy for localized sebaceous carcinoma of the eyelid: A retrospective analysis\n          of 83 patients","volume":"60","author":"Y Takagawa","year":"2019","journal-title":"J Radiat Res"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.2147\/OTT.S130371","article-title":"Ocular basal cell carcinoma: A brief literature review of clinical diagnosis and\n          treatment","volume":"10","author":"Y Shi","year":"2017","journal-title":"Onco Targets Ther"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/IOP.0b013e3182831bf3","article-title":"Targeted therapy for orbital and periocular basal cell carcinoma and squamous cell\n          carcinoma","volume":"29","author":"V Yin","year":"2013","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1038\/s41433-020-01291-2","article-title":"Neoadjuvant vismodegib in the management of locally advanced periocular basal cell\n          carcinoma","volume":"35","author":"D S Curragh","year":"2021","journal-title":"Eye (Basingstoke)"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.molonc.2014.09.003","article-title":"Smoothened (SMO) receptor mutations dictate resistance tovismodegib in basal cell\n          carcinoma","volume":"9","author":"S Pricl","year":"2015","journal-title":"Mol Oncol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13045-022-01311-6","article-title":"Emerging strategies to overcome resistance to third-generation EGFR inhibitors","volume":"15","author":"K Shi","year":"2022","journal-title":"J Hematol Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.hoc.2018.09.005","article-title":"Cutaneous melanoma\u2013A review in detection, staging, and management","volume":"33","author":"R I Hartman","year":"2019","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.3390\/cancers13112822","article-title":"New targeted therapies and immunotherapies for locally advanced periocular malignant\n          tumours: Towards a new \u2018eye-sparing\u2019 paradigm?","volume":"13","author":"A Martel","year":"2021","journal-title":"Cancers (Basel)"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1177\/1758834014566428","article-title":"Management of BRAF and MEK inhibitor toxicities in patients with metastatic\n          melanoma","volume":"7","author":"S J Welsh","year":"2015","journal-title":"Ther Adv Med Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1080\/08820538.2019.1620813","article-title":"Advances in immunotherapy and periocular malignancy","volume":"34","author":"L A Habib","year":"2019","journal-title":"Semin Ophthalmol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/S1470-2045(21)00126-1","article-title":"Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an\n          open-label, multi-centre, single-arm, phase 2 trial","volume":"22","author":"A J Stratigos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"12","key":"ref24","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005082","article-title":"Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in\n          basal cell carcinoma and cutaneous squamous-cell carcinoma","volume":"10","author":"P A Ascierto","year":"2022","journal-title":"J Immunother Cancer"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/J.EJCA.2022.09.013","article-title":"Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced\n          basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER\n          AcS\u00e9 NIVOLUMAB trial","volume":"177","author":"M V\u00e9ron","year":"2022","journal-title":"Eur J Cancer"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.jaad.2018.08.017","article-title":"Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated,\n          proof-of-concept study","volume":"80","author":"A LS Chang","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/nejmoa1805131","article-title":"PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma","volume":"379","author":"M R Migden","year":"2018","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S1470-2045(19)30728-4","article-title":"Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an\n          open-label, phase 2, single-arm trial","volume":"21","author":"M R Migden","year":"2020","journal-title":"Lancet Oncol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1158\/1078-0432.CCR-21-0585","article-title":"Pilot phase II trial of neoadjuvant immunotherapy in locoregionally advanced, resectable\n          cutaneous squamous cell carcinoma of the head and neck","volume":"27","author":"R Ferrarotto","year":"2021","journal-title":"Clinical Cancer Research"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1002\/cncr.34463","article-title":"A phase 2 study of first-line nivolumab in patients with locally advanced or metastatic\n          cutaneous squamous-cell carcinoma","volume":"128","author":"R R Munhoz","year":"2022","journal-title":"Cancer"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1200\/JCO.19.03054","article-title":"Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma:\n          A single-arm phase II trial (KEYNOTE-629)","volume":"38","author":"J J Grob","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1097\/IOP.0000000000001351","article-title":"Massive periocular squamous cell carcinoma with response to pembrolizumab\n          (Keytruda)","volume":"35","author":"J R Conger","year":"2019","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/IIO.0000000000000306","article-title":"Avelumab as an emerging therapy for eyelid and periocular Merkel cell carcinoma","volume":"60","author":"G A Garcia","year":"2020","journal-title":"Int Ophthalmol Clin"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ajo.2020.07.031","article-title":"High expression of programmed death ligand 1 and programmed death ligand 2 in ophthalmic\n          sebaceous carcinoma: The case for a clinical trial of checkpoint inhibitors","volume":"220","author":"N Wolkow","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1001\/jamaoncol.2023.0147","article-title":"Efficacy and safety of nivolumab plus ipilimumab vs. nivolumab alone for treatment of\n          recurrent or metastatic squamous cell carcinoma of the head and Neck","volume":"9","author":"K J Harrington","year":"2023","journal-title":"JAMA Oncol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.ajo.2023.02.010","article-title":"Ipilimumab and nivolumab for treatment of eyelid spindle cell melanoma","volume":"250","author":"M K Shoji","year":"2023","journal-title":"Am J Ophthalmol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/nejmoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"H A Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"R W Jenkins","year":"2018","journal-title":"Br J Cancer"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/IOP.0000000000000398","article-title":"Neoadjuvant systemic chemotherapy in the management of extensive eyelid sebaceous gland\n          carcinoma: A study of 10 cases","volume":"32","author":"S Kaliki","year":"2016","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1159\/000515857","article-title":"Neoadjuvant systemic chemotherapy in sebaceous gland carcinoma of the eyelid: A\n          retrospective study","volume":"7","author":"S Verma","year":"2021","journal-title":"Ocul Oncol Pathol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"121","DOI":"10.7181\/acfs.2018.02089","article-title":"Upper eyelid merkel cell carcinoma treated with neoadjuvant chemotherapy and surgical\n          excision","volume":"20","author":"V Toto","year":"2019","journal-title":"Arch Craniofac Surg"},{"key":"ref42","first-page":"162","article-title":"Chemotherapy of eyelid and peritorbital tumors","volume":"83","author":"M N Luxenberg","year":"1985","journal-title":"Trans Am Ophthalmol Soc"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.675873","article-title":"Prior Therapy with pegylated-interferon Alfa-2b improves the efficacy of adjuvant\n          pembrolizumab in resectable advanced melanoma","volume":"11","author":"D D Jia","year":"2021","journal-title":"Front Oncol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/JNCI\/84.4.235","article-title":"13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced\n          squamous cell carcinoma of the skin","volume":"84","author":"S M Lippman","year":"1992","journal-title":"J Natl Cancer Inst"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1097\/ICO.0b013e3181967338","article-title":"Intralesional interferon alpha-2b therapy for adnexal Kaposi sarcoma","volume":"28","author":"Y A Qureshi","year":"2009","journal-title":"Cornea"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s00347-020-01072-y","article-title":"Therapiealternativen zur chirurgischen Versorgung maligner Lidtumoren und deren\n          Vorl\u00e4uferstufen","volume":"117","author":"C Girbardt","year":"2020","journal-title":"Der Ophthalmologe"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1136\/bjo.2009.176099","article-title":"Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: A\n          10-year review of treatment outcomes and complications","volume":"94","author":"H C Russell","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.prp.2014.10.006","article-title":"Comparison of HER2 gene amplification and KRAS alteration in eyelid sebaceous carcinomas\n          with that in other eyelid tumors","volume":"211","author":"M J Kwon","year":"2015","journal-title":"Pathol Res Pract"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"200244","DOI":"10.1016\/J.TVR.2022.200244","article-title":"Synergistic targeting of the PI3K\/mTOR and MAPK\/ERK pathways in Merkel cell\n          carcinoma","volume":"14","author":"A Temblador","year":"2022","journal-title":"Tumour Virus Res"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/path.4759","article-title":"Next-generation sequencing identifies high frequency of mutations in potentially\n          clinically actionable genes in sebaceous carcinoma","volume":"240","author":"M T Tetzlaff","year":"2016","journal-title":"J Pathol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1055\/s-2006-926809","article-title":"Das Talgdr\u00fcsenkarzinom der Augenlider \u2013 Fallbeschreibung und Literatur\u00fcbersicht","volume":"223","author":"K K Warnecke","year":"2006","journal-title":"Klin Monbl Augenheilkd"}],"container-title":["Klinische Monatsbl\u00e4tter f\u00fcr Augenheilkunde"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2255-5937.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T22:54:35Z","timestamp":1785279275000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2255-5937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,27]]},"references-count":48,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2024,3,20]]},"published-print":{"date-parts":[[2024,3]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2255-5937","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0023-2165","1439-3999"],"issn-type":[{"value":"0023-2165","type":"print"},{"value":"1439-3999","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,27]]}}}